Diabetes mellitus and the St Vincent Declaration. The economic implications
- PMID: 10155319
- DOI: 10.2165/00019053-199507040-00004
Diabetes mellitus and the St Vincent Declaration. The economic implications
Abstract
Diabetes mellitus imposes significant costs both on individuals and on healthcare delivery systems. Chronic diseases such as diabetes mellitus have lifetime costs, and so resources spent on interventions now may not bring benefits, in terms of reduced complications, for many years. In Europe, the St Vincent Declaration, which includes targets for the reduction of diabetes mellitus-related complications, is an important initiative set up to address quality and education issues relevant to people with diabetes mellitus. The Declaration is to be welcomed as focusing attention on diabetes mellitus, and its implementation may lead to a reduction in healthcare expenditure on complications in future years. The aims of the St Vincent Declaration are to set goals and 5-year targets to improve quality of life and life expectancy for people with diabetes mellitus and to reduce the serious complications associated with the disease. Achievement of these targets will depend on good organisation and management of services to people with diabetes mellitus, but the aims are a clear signal that the importance of prevention and education have been recognised. A major barrier to the implementation of the Declaration is financial. If more people are diagnosed and treated, more services will be required. This will incur costs, although future benefits will be gained in terms of a reduction in complications.
Similar articles
-
Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee.Diabet Med. 1993 May;10(4):371-7. doi: 10.1111/j.1464-5491.1993.tb00083.x. Diabet Med. 1993. PMID: 8508624
-
The impact of diabetes mellitus on healthcare costs in Italy.Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-19. doi: 10.1586/erp.11.78. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098288 Review.
-
Model-based evaluation of diabetic foot prevention strategies in Austria.Health Care Manag Sci. 2005 Nov;8(4):253-65. doi: 10.1007/s10729-005-4136-6. Health Care Manag Sci. 2005. PMID: 16379409 Review.
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Health-related quality of life in diabetic people with different vascular risk.BMC Public Health. 2012 Sep 20;12:812. doi: 10.1186/1471-2458-12-812. BMC Public Health. 2012. PMID: 22994940 Free PMC article.
-
Effects of Diabetic Complications on Health-Related Quality of Life Impairment in Vietnamese Patients with Type 2 Diabetes.J Diabetes Res. 2020 Jan 23;2020:4360804. doi: 10.1155/2020/4360804. eCollection 2020. J Diabetes Res. 2020. PMID: 32047823 Free PMC article.
-
An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System.Int J Environ Res Public Health. 2020 Jun 21;17(12):4456. doi: 10.3390/ijerph17124456. Int J Environ Res Public Health. 2020. PMID: 32575853 Free PMC article.
-
Lifestyle and metabolic risk factors, and diabetes mellitus prevalence in European countries from three waves of the European Health Interview Survey.Sci Rep. 2024 May 21;14(1):11623. doi: 10.1038/s41598-024-62122-y. Sci Rep. 2024. PMID: 38773149 Free PMC article.
-
Costs of diabetes. A methodological analysis of the literature.Pharmacoeconomics. 1999 Jun;15(6):583-95. doi: 10.2165/00019053-199915060-00006. Pharmacoeconomics. 1999. PMID: 10538331
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical